JP2024540015A5 - - Google Patents
Info
- Publication number
- JP2024540015A5 JP2024540015A5 JP2024525058A JP2024525058A JP2024540015A5 JP 2024540015 A5 JP2024540015 A5 JP 2024540015A5 JP 2024525058 A JP2024525058 A JP 2024525058A JP 2024525058 A JP2024525058 A JP 2024525058A JP 2024540015 A5 JP2024540015 A5 JP 2024540015A5
- Authority
- JP
- Japan
- Prior art keywords
- braf
- cancer
- inhibitor
- raf
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272899P | 2021-10-28 | 2021-10-28 | |
| US63/272,899 | 2021-10-28 | ||
| PCT/US2022/078771 WO2023076991A1 (en) | 2021-10-28 | 2022-10-27 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540015A JP2024540015A (ja) | 2024-10-31 |
| JP2024540015A5 true JP2024540015A5 (https=) | 2025-11-05 |
Family
ID=86158717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525058A Pending JP2024540015A (ja) | 2021-10-28 | 2022-10-27 | 異常な細胞成長を処置するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250009746A1 (https=) |
| EP (1) | EP4422617A4 (https=) |
| JP (1) | JP2024540015A (https=) |
| KR (1) | KR20240095266A (https=) |
| CN (1) | CN118510505A (https=) |
| AU (1) | AU2022376939A1 (https=) |
| CA (1) | CA3235499A1 (https=) |
| IL (1) | IL312248A (https=) |
| MX (1) | MX2024005024A (https=) |
| WO (1) | WO2023076991A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2024054591A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| TW202517624A (zh) * | 2023-07-03 | 2025-05-01 | 美商醫療免疫工程公司 | Mek免疫腫瘤抑制劑醫藥組合物 |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668055B2 (en) * | 2013-12-20 | 2020-06-02 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of ERK and RAF inhibitors |
| US20170112865A1 (en) * | 2014-05-21 | 2017-04-27 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| JP6864990B2 (ja) * | 2015-04-16 | 2021-04-28 | 日東電工株式会社 | Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| KR20200037820A (ko) * | 2017-08-07 | 2020-04-09 | 에볼 사이언스 엘엘씨 | 암을 치료하기 위한 조합 |
| JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
-
2022
- 2022-10-27 EP EP22888488.8A patent/EP4422617A4/en active Pending
- 2022-10-27 CA CA3235499A patent/CA3235499A1/en active Pending
- 2022-10-27 CN CN202280078087.7A patent/CN118510505A/zh active Pending
- 2022-10-27 MX MX2024005024A patent/MX2024005024A/es unknown
- 2022-10-27 KR KR1020247017024A patent/KR20240095266A/ko active Pending
- 2022-10-27 US US18/702,569 patent/US20250009746A1/en active Pending
- 2022-10-27 IL IL312248A patent/IL312248A/en unknown
- 2022-10-27 WO PCT/US2022/078771 patent/WO2023076991A1/en not_active Ceased
- 2022-10-27 JP JP2024525058A patent/JP2024540015A/ja active Pending
- 2022-10-27 AU AU2022376939A patent/AU2022376939A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540015A5 (https=) | ||
| JP2022009090A5 (https=) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2019532051A5 (https=) | ||
| JP2013507415A5 (https=) | ||
| AU2015360095A1 (en) | Quinoline derivative against non-small cell lung cancer | |
| JP2024505680A5 (https=) | ||
| KR102490547B1 (ko) | 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물 | |
| JP2021169474A (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| WO2016091165A1 (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| EP3957631A1 (en) | Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma | |
| TW202402290A (zh) | 癌症治療 | |
| TWI866427B (zh) | 雌激素受體降解劑之給藥方案 | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| JP2024502446A5 (https=) | ||
| WO2025157162A1 (zh) | Fak抑制剂与kras g12c抑制剂的联用 | |
| CN100408036C (zh) | 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途 | |
| WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| WO2020057536A1 (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
| CN117462553A (zh) | 药物组合产品以及组合疗法 | |
| US20210205272A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| EP3854396A1 (en) | Quinoline derivative used for treating small cell lung cancer | |
| Mathew et al. | Clinical Evidence of Regorifenib in Metastatic Colorectal Cancer: A Case Report | |
| CN115487188A (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| WO2016091167A1 (zh) | 抗肺鳞癌的喹啉衍生物 |